TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
2.870
-0.100 (-3.37%)
At close: Aug 21, 2026, 4:00 PM EDT
3.050
+0.180 (6.27%)
After-hours: Aug 21, 2026, 7:56 PM EDT

TransCode Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-25.36-19.19-15.66-19.42-18.63-6.15
Net Income
-46.28-36.27-16.79-18.55-17.56-6.84
Earnings Per Share
-51.08-52.59-1336.64---
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.3817.815.812.774.9820.84
Total Debt
0.65-0.040.45--
Net Cash (Debt)
7.7317.815.772.324.9820.84
Net Cash Growth
4.83%208.58%149.15%-53.45%-76.11%-
Net Cash Per Share
8.5325.83459.69---

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-22.61-19.52-13.34-18.07-15.76-5.27
Capital Expenditures
-0.01-0.01-0.02-0.04-0.1-0.25
Free Cash Flow
-22.61-19.52-13.36-18.11-15.86-5.52
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.